Cytokine of TNF-α, IL-6, and IFN-γ reached the peak at 2 h after rituximab infusion in chronic lymphocytic leukemia (CLL) patients.58 Besides, TGN1412, a superagonist anti-CD28 humanized mAb, can directly stimulate T cells and treatment of healthy volunteers with TGN1412 led to severe CRS and increased disseminated intravascular coagulation (DIC).59 This evidence concerns the gene CD28 and B-cell chronic lymphocytic leukemia.